Hansa Biopharma's Phase 3 ConfIdeS Trial Results to be Highlighted at ATC 2026

Hansa Biopharma to Present ConfIdeS Trial Results at ATC 2026

Hansa Biopharma AB, a leading biopharmaceutical company based in Lund, Sweden, has recently disclosed significant news regarding its research into kidney transplantation. On May 26, 2026, the company revealed that results from its US Phase 3 ConfIdeS trial have been chosen for a late-breaking abstract presentation at the American Transplant Congress (ATC) scheduled for June 22, 2026, in Boston.

The ConfIdeS trial focuses on highly sensitized kidney transplant patients who possess donor-specific antibodies that complicate their ability to receive a transplant. Traditional methods often struggle to find compatible donors for these individuals, making Hansa's research particularly crucial. The trial aims to evaluate the efficacy and safety of Imlifidase, an innovative enzyme therapy that cleaves immunoglobulin G (IgG) antibodies, thereby facilitating improved transplantation opportunities.

Significance of the Trial Results

The spotlight will be on the presentation that highlights the 12-month results, including the primary endpoint of estimated Glomerular Filtration Rate (eGFR) and key safety results. Dr. Robert Montgomery, a prominent figure in the transplant field and part of the New York University Langone Transplant Institute, will lead the presentation on behalf of the ConfIdeS study group.

The specific title of the session is "Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared with Control," abstract number 730. This comprehensive research offers insights into the critical improvements in kidney function outcomes for patients who typically have a poor prognosis due to their highly sensitized status.

Understanding Highly Sensitized Patients

Highly sensitized patients represent about 10-15% of those on kidney transplant waiting lists in the US and Europe. Their antibodies can lead to severe complications, including transplant rejection. The presence of donor-specific antibodies makes finding a compatible organ a challenge, often leading to extended waiting periods and increased health risks.

The changing landscape brought by therapies like Imlifidase is pivotal. By potentially increasing transplant eligibility, Hansa's research aims to reduce the time these patients spend on waiting lists and improve their overall survival rates.

Imlifidase and Its Clinical Impact

Imlifidase, commercially known as IDEFIRIX in the EU and UK, is a breakthrough therapy that targets and degrades IgG antibodies to modulate the immune response in kidney transplant patients. With its rapid onset within hours post-administration, Imlifidase allows previously ineligible patients to receive transplants, fundamentally transforming treatment paradigms.

Conditional approvals have placed this enzyme therapy as a front-runner in addressing the immunological challenges faced by sensitized individuals. As the FDA evaluates the Biologics License Application (BLA) for Imlifidase, the results from the ConfIdeS trial will contribute to a broader understanding of its efficacy and safety, potentially influencing future regulations and treatment protocols.

Hansa Biopharma's Vision

Hansa Biopharma positions itself at the forefront of immunomodulatory research with a commitment to addressing unmet medical needs in areas such as transplantation and autoimmune diseases. Their proprietary technology harnesses the unique properties of IgG-cleaving enzymes, promising to enhance care for individuals facing complex immune disorders.

As we await the presentation at ATC 2026, the healthcare community anticipates impactful outcomes from the ConfIdeS trial that could greatly benefit those struggling with kidney transplants. The findings are expected to not only showcase Hansa's innovative approach but also set new benchmarks for the treatment of highly sensitized patients.

Conclusion

The ATC 2026 presentation of the ConfIdeS trial results marks a significant milestone for Hansa Biopharma and the health sector at large. The potential of Imlifidase offers hope to many patients whose paths to recovery have been hindered by the complex nature of their immunological profiles. As we look forward to June 22, 2026, the medical community stands united in anticipation of the advancements that could reshape kidney transplantation.

For more information regarding Hansa Biopharma and its innovative therapies, visit Hansa biopharma's website.